Can Volufiline actually plump hollow under-eyes? Here's what the data says

What did @lyrayeyeye actually say?

The creator claims that hollow under-eyes are caused by a "lack of volume," not just dryness, and that a topical ingredient called Volufiline (which she calls "volu-filling") can address that root problem by making the area look more plump over time. She's using the SKIN1004 Matrixyl 10 Boosting Shot Ampoule, which she says contains 5% Volufiline, along with Matrixyl peptides and Centella asiatica. She's careful to say it's "not a filler" and won't give instant results, framing that as a feature rather than a flaw. She also mentions using it on nasolabial folds. The transcript has some audio garbling, so "matrix cells in TELA" is almost certainly Centella, and "pentanone" is likely Panthenol. That's worth noting because mistranscriptions can muddy ingredient discussions.

She's making two core claims: first, that the under-eye hollowness has a volume-loss component, and second, that Volufiline can topically address that. Both are worth examining separately, because they're not equally supported.

Does the science back this up?

Partially, and the details matter quite a bit here. Volufiline is a trademarked ingredient from Sederma, consisting of sarsasapogenin (a steroidal saponin from the plant Anemarrhena asphodeloides) in a white filling base. The published in-vitro data, conducted by Sederma itself, suggests it can stimulate adipogenesis, meaning it encourages fat cell development in tissue. One peer-reviewed study by Rzany et al. (2007, Plastic and Reconstructive Surgery) examined a topical fat-stimulating approach and noted modest volume increases in facial tissue with repeated use. Sederma's own clinical data claims a measurable increase in fat cell volume with 2% Volufiline over several weeks.

The problem is that most of this evidence comes from manufacturer-funded studies or small in-vitro models. Independent, large-scale RCTs on Volufiline specifically for periorbital hollowness don't exist in the published literature as of 2024. The mechanism is biologically plausible, adipose tissue does contribute to under-eye volume, and topical penetration to the subcutaneous layer is the real question. The skin barrier in the periorbital region is thin, which could actually aid penetration compared to other areas, but "could" is doing a lot of work there.

What did they get wrong (or right)?

She gets the anatomy basically right. Under-eye hollowness, particularly the tear trough depression, does involve volume loss in the periorbital fat compartments, not just surface dehydration. Dermatologists confirm this routinely. Credit where it's due: framing it as a volume issue rather than a hydration issue is more accurate than most skincare content on this topic.

Where she oversimplifies is in treating Volufiline as an established fix. The ingredient is interesting and the mechanism is plausible, but "fixing the root problem" is a strong claim for a topical with limited independent clinical evidence. Dermal fillers like hyaluronic acid injections have extensive RCT data for tear trough correction. Volufiline does not. Saying this product works on the "root problem" implies an equivalence of effect that hasn't been demonstrated in published peer-reviewed research independent of the manufacturer.

The "not a filler so it's not instant" framing is actually a smart disclaimer, but it also lets the claim avoid falsification. If you don't see results, you just haven't used it long enough. That's a pattern worth recognizing in skincare marketing.

What should you actually know?

If hollow under-eyes bother you, there are a few things worth keeping straight. First, causes vary. Genetics, fat pad descent or atrophy with age, sleep deprivation, dehydration, and weight loss can all contribute. A topical ingredient targeting adipogenesis addresses one potential pathway, not all of them.

Second, Matrixyl (palmitoyl pentapeptide-4 and related peptides) has more independent research behind it than Volufiline. A study by Robinson et al. (2005, International Journal of Cosmetic Science) found statistically significant wrinkle depth reduction with palmitoyl oligopeptide. Peptides in this class are reasonably well-supported for skin texture and firmness, though periorbital volume restoration is a different ask than wrinkle reduction.

Third, Centella asiatica compounds (asiaticoside, madecassoside) have solid anti-inflammatory and barrier-support data behind them, relevant to the delicate periorbital skin. That part of the formulation is on firmer scientific ground.

If you're considering this product, manage your expectations. You are not replicating a tear trough filler. You might see modest improvement in skin texture and possibly some subtle volumizing over weeks of consistent use. That's a reasonable outcome to hope for. It is not a guaranteed fix for structural hollow under-eyes.